FibroBiologics, Inc. (FBLG) stock
FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.84−0.06 (-6.72%)
Close on Nov 18, 2026Market cap $5.59MP/E –Yield –
FibroBiologics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
FibroBiologics's operating income for the twelve months ending Jun 30, 2026 was -$16.73M. For fiscal 2025 it was -$16.65M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.65M | – |
| FY2024 | Dec 31, 2024 | -$13.74M | – |
| FY2023 | Dec 31, 2023 | -$8.89M | – |
| FY2022 | Dec 31, 2022 | -$4.47M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.07M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.59M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.04M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.49M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.53M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.71M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.35M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.45M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.48M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.05M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.09M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.27M | – |
See a number that looks wrong?